|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
One further characterized cytotoxic CD8(+) T cell clone, that released TNF-alpha, IFN-gamma, and granzyme B upon co-incubation with the autologous tumor cells, was shown to be restricted by the remaining HLA-A11 allele, which was also shown to be expressed in the tumor tissue.
|
16924494 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In p50<sup>-/-</sup> mice, total tumor CD4 T cells are threefold more abundant, whereas CD8 T-cell numbers are unchanged, and both produce increased IFNγ and Granzyme B. Naïve splenic p50<sup>-/-</sup> CD8 T cells manifest increased activation, whereas naïve p50<sup>-/-</sup> and WT CD4 T cells show similar Th1, Th2, and Th17 polarization.
|
30030559 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, the activation/suppression marker values of the lymphocytes (i.e., such as PD-1, ICOS, Granzyme B and the PD-1/CD8 ratio) in the primary tumor were correlated with values in the metastatic tumor.
|
29614981 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Saline-treated tumors increased 24-fold, whereas tumors treated with GrB/scFvMEL showed a significant tumor growth delay increasing four-fold.
|
16611405 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
More importantly, NK-92-S3KD immunotherapy increases the production of not only IFNγ, but also granzyme B and perforin in tumors; therefore, inhibiting cancer progression in two xenograft mouse models with human hepatoma (HepG2) and melanoma (A375).
|
29915022 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
|
26806809 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
On day 12 and day 29, the immune-activation in the peripheral blood, tumors, and spleens were analyzed. rAd.DCN.GM increased CD8<sup>+</sup> T lymphocytes in the blood, upregulated perforin and granzyme B in the tumors, inhibited transforming growth factor beta expression, and promoted dendritic-cell production in the spleen.
|
28530155 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, tumor tissue excised from GrB/4D5/26-treated mice showed excellent delivery of GrB to tumors and a dramatic induction of apoptosis compared with saline treatment.
|
23493312 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The antitumor immunity in IL-1β-deficient mice includes activated CD8<sup>+</sup> lymphocytes expressing IFN-γ, TNF-α, and granzyme B; these cells infiltrate tumors and induce regression.
|
30545915 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Reductions in GzmB in intratumoral CD8+ T cells in combination with the changes in tumor microenvironment that maintain the ability of CSCs to self-renew and even confer this capability to the nonstem population are compatible with reduced immunosurveillance and adverse tumor outcomes in animal models of OSA.
|
28364502 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Paired t test showed an increase of GRANZYME-B+ lymphocytes density in LN metastasis compared to the corresponding primary tumor, suggesting that LN metastasis is enriched with activated immune cells.
|
28730569 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, in some tumor systems the immunosurveillance failure against cancer cells has been related to the presence of the granzyme B inhibitor PI-9.
|
27121069 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Targeting granzyme B to tumor cells using a yoked human chorionic gonadotropin.
|
21327682 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In NK cells and CTLs the levels of active cathepsin C and of granzyme B are dependent on the concentration of monomeric, active cystatin F. In tumour microenvironment, inactive dimeric cystatin F can be secreted from tumour cells or immune cells and further taken up by the cytotoxic cells.
|
29748898 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we provide a preclinical proof of concept for the use of granzyme B, a downstream effector of tumoral cytotoxic T cells, as an early biomarker for tumors responding to immunotherapy.
|
28461564 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results show that targeted delivery of GrB to tumor vascular endothelial cells or to tumor cells activates apoptotic cascades and this completely human construct may have significant therapeutic potential.
|
23858102 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The combination also promoted IFNg, IL12 and granzyme B production in the tumor microenvironment and decreased the formation of liver metastasis in a very early phase of tumor development, enabling 90% survival.
|
30356111 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Similarly, there was robust granzyme B staining localizing to the tumors; affirming the presence of cytotoxic immune cells within the tumor.
|
29930558 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, the use of CTL expressing a fluorescent granzyme B (GZMB-Tom) showed a delay in the migration of cytotoxic granules to the tumour interaction site, as well as a partially deficient GZMB-Tom exocytosis in response to the melanoma cells.
|
27716898 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Cytolytic proteins, such as granzyme B and perforin, have been shown to play crucial pathophysiological roles in NK/T cell neoplasms and have also been utilized for diagnostic purposes.
|
22890551 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Type I interferon suppresses tumor growth through activating the STAT3-granzyme B pathway in tumor-infiltrating cytotoxic T lymphocytes.
|
31228946 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
T cell cytotoxicity was mediated via granzyme B release and mediated enhanced tumor control <i>in vivo</i>.
|
30214445 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We studied 11 cases of nodal cytotoxic T-cell lymphoma, which express the CD8+ phenotype and cytotoxic molecules (T-cell intracellular antigen-1, granzyme B and perforin), to characterize the clinicopathologic spectrum of these neoplasms.
|
12429791 |
2002 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Including CTL and GZMB scores simultaneously in the model significantly improved the predictive performance of the models for all-cause and colorectal cancer-related death.<b>Conclusions:</b> Higher tumor infiltration with CTL and GZMB cells is associated with improved all-cause and cancer-specific survival of colorectal cancer patients.<b>Impact:</b> Both the number of CTLs and GZMB appear to be useful prognostic factors in colorectal cancer, irrespective of stage.
|
27979806 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In vivo antilymphoma activity of HSP105 engagement was associated with a significant local increase of Granzyme B(+) killer cells that very likely contributed to the tumor-restricted necrosis.
|
21860023 |
2011 |